Opportunities and challenges in using real-world data for health care
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Real-world data (RWD) continue to emerge as a new source of clinical evidence. Although the best-known use case of RWD has been in drug regulation, RWD are being generated and used by many other parties, including biopharmaceutical companies, payors, clinical researchers, providers, and patients. In this Review, we describe 21 potential uses for RWD across the spectrum of health care. We also discuss important challenges and limitations relevant to the translation of these data into evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 1×
“For example, trials of widely used antidiabetic medications were needed to confirm serious risks such as those of bone fractures (12, 13) and amputations (14).”
Result10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“For instance, 10-year and 30-year follow-up data from the UK Prospective Diabetes Study and the Diabetes Control and Complications Trial, of type 2 and type 1 diabetes mellitus, respectively, have demonstrated a long-term reduction in disease complications following a strategy of intensive glycemic control (41, 42).”
BackgroundGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Clinical assessment incorporating a personal genome
Ashley, E. A., Butte, A. J., Wheeler, M. T., Chen, R., Klein, T. E., Dewey, F. E., Dudley, J. T., Ormond, K. E., Pavlovic, A., Morgan, A. A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60452-7 · Cited by 674
Self-citationThe “Efficacy-Effectiveness Gap”: Historical Background and Current Conceptualization
Nordon, C., Karcher, H., Groenwold, R. H. H., Ankarfeldt, M. Z., Pichler, F., Chevrou-Severac, H., Rossignol, M., Abbe, A., & Abenhaim, L. (2016) · Value in Health · doi:10.1016/j.jval.2015.09.2938 · Cited by 177
Remission of Crohn's disease on bupropion
Kast, R. E., & Altschuler, E. L. (2001) · Gastroenterology · doi:10.1053/gast.2001.29467 · Cited by 58 · cited 1×
“These include beneficial ones, such as the anti-TNF effect of bupropion in the setting of Crohn’s disease (9, 10).”
BackgroundPerforming an Informatics Consult: Methods and Challenges
Schuler, A., Callahan, A., Jung, K., & Shah, N. H. (2018) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2017.12.023 · Cited by 37 · cited 1×
“Another exciting version of this idea is informatics as a clinical consultation service — one that makes EHR-powered data and recommendations accessible to providers within the setting of existing clinical reimbursement frameworks (52).”
Background
Cited by
Harnessing EHR data for health research
Tang, A. S., Woldemariam, S. R., Miramontes, S., Norgeot, B., Oskotsky, T. T., & Sirota, M. (2024) · Nature Medicine · doi:10.1038/s41591-024-03074-8 · Cited by 87
“EHRs provide an extensive, rich, longitudinal dataset with great opportunity for answering scientific questions, developing AI models, and advancing therapeutics in human health and disease 4,51,76,77 .”
Artificial Intelligence: Exploring the Future of Innovation in Allergy Immunology
MacMath, D., Chen, M., & Khoury, P. (2023) · Current Allergy and Asthma Reports · doi:10.1007/s11882-023-01084-z · Cited by 62
Metadata
- Authors
- Rudrapatna, V. A., & Butte, A. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2020-02-03
- Volume
- 130
- Issue
- 2
- Pages
- 565-574
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3004278594
- Cited by
- 174
- References
- 8
- FWCI
- 18.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.